Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N, Okanoue T, Itoh Y, Mochida S, Toyoda H, Yoshiji H, Takaki S, Yatsuzuka N, Yodoya E, Iwasa T, Fujimoto G, Robertson MN, Black S, Caro L, Wahl J. Kumada H, et al. Among authors: mochida s. J Gastroenterol. 2017 Apr;52(4):520-533. doi: 10.1007/s00535-016-1285-y. Epub 2016 Nov 21. J Gastroenterol. 2017. PMID: 27873094 Free PMC article. Clinical Trial.
Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial.
Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M. Shindo M, et al. Among authors: mochida s. Hepatol Int. 2009 Sep;3(3):445-52. doi: 10.1007/s12072-009-9135-0. Epub 2009 May 23. Hepatol Int. 2009. PMID: 19669249 Free PMC article.
Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Imai Y, Chikayama T, Nakazawa M, Watanabe K, Ando S, Mizuno Y, Yoshino K, Sugawara K, Hamaoka K, Fujimori K, Inao M, Nakayama N, Oka M, Nagoshi S, Mochida S. Imai Y, et al. Among authors: mochida s. J Gastroenterol. 2012 Feb;47(2):179-86. doi: 10.1007/s00535-011-0475-x. Epub 2011 Oct 6. J Gastroenterol. 2012. PMID: 21976133
The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K. Narahara Y, et al. Among authors: mochida s. J Gastroenterol. 2012 Mar;47(3):313-20. doi: 10.1007/s00535-011-0485-8. Epub 2011 Oct 25. J Gastroenterol. 2012. PMID: 22038555 Clinical Trial.
A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.
Nagoshi S, Koshima Y, Nakamura I, Funyu J, Sekine C, Harada Y, Nishikawa K, Yoshida T, Matsui A, Sotome N, Toshima K, Takegoshi S, Shiomi M, Tanaka M, Saito A, Fujiwara K, Mochida S. Nagoshi S, et al. Among authors: mochida s. Intern Med. 2012;51(1):9-15. doi: 10.2169/internalmedicine.51.6237. Epub 2012 Jan 1. Intern Med. 2012. PMID: 22214617 Free article. Clinical Trial.
359 results